MII IG Kerndatensatz-Modul Molekulares Tumorboard, published by Medizininformatik-Initiative. This guide is not an authorized publication; it is the continuous build for version 2026.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/medizininformatik-initiative/kerndatensatzmodul-molekulares-tumorboard/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Mirvetuximab soravtansine - XML Representation

Raw xml | Download

<MedicationRequest xmlns="http://hl7.org/fhir">
  <id value="mii-exa-mtb-medication-request-mirvetuximab"/>
  <meta>
    <profile
             value="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung|2026.0.0"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: MedicationRequest mii-exa-mtb-medication-request-mirvetuximab</b></p><a name="mii-exa-mtb-medication-request-mirvetuximab"> </a><a name="hcmii-exa-mtb-medication-request-mirvetuximab"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-mii-pr-mtb-therapieempfehlung.html">MII PR MTB Therapieempfehlung Systemische Therapieversion: null2026.0.0)</a></p></div><p><b>MII EX MTB Empfehlung Priorität</b>: 1</p><p><b>MII EX MTB Empfehlung Evidenzgraduierung</b>: <span title="Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad m1A}">m1A</span></p><p><b>MII EX MTB Empfehlung Publikation</b>: <code>http://doi.org</code>/10.1200/JCO.2022.40.16_suppl.5512</p><p><b>MII EX MTB Empfehlung Publikation</b>: <code>http://www.ncbi.nlm.nih.gov/pubmed</code>/38055253</p><p><b>status</b>: Completed</p><p><b>intent</b>: Proposal</p><p><b>medication</b>: <span title="Codes:{http://fdasis.nlm.nih.gov 98DE7VN88D}, {http://fhir.de/CodeSystem/bfarm/atc L01FX26}, {http://fhir.de/CodeSystem/bfarm/atc L01FX}">MIRVETUXIMAB SORAVTANSINE</span></p><p><b>subject</b>: <a href="Patient-PatientKimMusterperson.html">Kim Musterperson  (no stated gender), DoB: 1956-03-14</a></p><p><b>authoredOn</b>: 2023-03-28</p><p><b>reasonReference</b>: <a href="Condition-PatientKimMusterperson-PrimaryDiagnosis-2.html">Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet</a></p><p><b>basedOn</b>: <a href="CarePlan-mii-exa-mtb-kim-musterperson-therapieplan.html">CarePlan: status = active; intent = plan; category = prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie); created = 2023-03-28</a></p></div>
  </text>
  <extension
             url="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-prioritaet">
    <valuePositiveInt value="1"/>
  </extension>
  <extension
             url="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-evidenzgraduierung">
    <valueCodeableConcept>
      <coding>
        <system
                value="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad"/>
        <code value="m1A"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension
             url="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-publikation">
    <valueIdentifier>
      <system value="http://doi.org"/>
      <value value="10.1200/JCO.2022.40.16_suppl.5512"/>
    </valueIdentifier>
  </extension>
  <extension
             url="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-publikation">
    <valueIdentifier>
      <system value="http://www.ncbi.nlm.nih.gov/pubmed"/>
      <value value="38055253"/>
    </valueIdentifier>
  </extension>
  <status value="completed"/>
  <intent value="proposal"/>
  <medicationCodeableConcept>
    <coding>
      <system value="http://fdasis.nlm.nih.gov"/>
      <code value="98DE7VN88D"/>
      <display value="MIRVETUXIMAB SORAVTANSINE"/>
    </coding>
    <coding>
      <system value="http://fhir.de/CodeSystem/bfarm/atc"/>
      <version value="2025"/>
      <code value="L01FX26"/>
      <display value="Mirvetuximab soravtansin"/>
    </coding>
    <coding>
      <system value="http://fhir.de/CodeSystem/bfarm/atc"/>
      <version value="2025"/>
      <code value="L01FX"/>
      <display
               value="Andere monoklonale Antikörper und Antikörper-Wirkstoff-Konjugate"/>
    </coding>
  </medicationCodeableConcept>
  <subject>🔗 
    <reference value="Patient/PatientKimMusterperson"/>
  </subject>
  <authoredOn value="2023-03-28"/>
  <reasonReference>🔗 
    <reference value="Condition/PatientKimMusterperson-PrimaryDiagnosis-2"/>
  </reasonReference>
  <basedOn>🔗 
    <reference value="CarePlan/mii-exa-mtb-kim-musterperson-therapieplan"/>
  </basedOn>
</MedicationRequest>